Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins by Zineh, Issam et al.
Epithelial Neutrophil-Activating Peptide (ENA-78), Acute
Coronary Syndrome Prognosis, and Modulatory Effect of
Statins
Issam Zineh
1*, Amber L. Beitelshees
1, Gregory J. Welder
1, Wei Hou
2, Nasser Chegini
3, Jun Wu
4, Sharon
Cresci
5, Michael A. Province
4, John A. Spertus
6
1Center for Pharmacogenomics and Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, Florida, United States of America,
2Department of Epidemiology and Health Policy Research, University of Florida College of Medicine, Gainesville, Florida, United States of America, 3Department of
Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida, United States of America, 4Division of Statistical Genomics, Center for Genome
Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America, 5Department of Medicine, Washington University School of Medicine,
St. Louis, Missouri, United States of America, 6Mid America Heart Institute, Kansas City, Missouri, United States of America
Abstract
Endothelial inflammation with chemokine involvement contributes to acute coronary syndromes (ACS). We tested the
hypothesis that variation in the chemokine gene CXCL5, which encodes epithelial neutrophil-activating peptide (ENA-78), is
associated withACSprognosis.We also investigated whether statinuse, a potentmodulator of inflammation,modifies CXCL5’s
association with outcomes and characterized the in vitro effect of atorvastatin on endothelial ENA-78 production. Using a
prospective cohort of ACS patients (n=704) the association of the CXCL5 2156 G.C polymorphism (rs352046) with 3-year all-
cause mortality was estimated with hazard ratios (HR). Models were stratified by genotype and race. To characterize the
influence of statins on this association, a statin*genotype interaction was tested. To validate ENA-78 as a statin target in
inflammation typical of ACS, endothelial cells (HUVECs) were treated with IL-1b and atorvastatin with subsequent
quantificationofCXCL5expressionandENA-78protein concentrations.C/Cgenotypewasassociatedwitha2.7-foldincreasein
3-year all-cause mortality compared to G/G+G/C (95%CI 1.19–5.87; p=0.017). Statins significantly reduced mortality in G/G
individualsonly(58%relativeriskreduction;p=0.0009).InHUVECs,atorvastatindose-dependentlydecreasedIL-1b-stimulated
ENA-78 concentrations (p,0.0001). Drug effects persisted over 48 hours (p,0.01). CXCL5 genotype is associated with
outcomes after ACS with potential statin modification of this effect. Atorvastatin lowered endothelial ENA-78 production
during inflammation typical of ACS. These findings implicate CXCL5/ENA-78 in ACS and the statin response.
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Introduction
Endothelial inflammation plays a major role in the development
and perpetuation of cardiovascular disease (CVD). The inflam-
matory process is complex, with various cellular mediators known
to contribute [1,2]. Multifunctional cytokines such as interleukin-1
(IL-1) play central roles in vascular inflammation. IL-1 produced
from monocytes, macrophages, and other cells can initiate
inflammation by inducing the production of chemokines from
endothelial cells [3,4]. Chemokines, in turn, propagate the process
through recruitment and activation of additional cellular media-
tors of inflammation including neutrophils. This process is
involved in many cardiovascular conditions including acute
coronary syndrome (ACS). Moreover, previous work has estab-
lished that monocyte chemokines such as monocyte chemoattrac-
tant protein-1 (MCP-1) are prognostic in ACS [5]. However, the
role of neutrophil chemokines in ACS has not been well described.
CXCL5 (MIM *600324 a.k.a. epithelial neutrophil-activating
peptide 78 or ENA-78) is a C-X-C chemokine that attracts and
activates neutrophils. Furthermore, CXCL5 expression has been
shown to be highly inducible in endothelial and vascular smooth
muscle cells by IL-1b [6–9]. Recent data have implicated CXCL5
and/or its receptors in congestive heart failure and ischemic
stroke, making CXCL5 a candidate gene for other manifestations of
CVD including ACS [10–12]. We previously identified a
2156G.C (rs352046) single nucleotide polymorphism (SNP) in
the CXCL5 promoter region to occur with high minor allele
frequency in the general population and associate with both
elevated plasma ENA-78 concentrations and leukocyte production
of ENA-78 [13]. We therefore tested the primary hypothesis that
this SNP is associated with 3-year all-cause mortality in a
prospectively enrolled cohort of ACS patients.
Beyond testing this association, we also sought to describe
potential associations with ACS therapies, namely statins, plausibly
capable of influencing inflammation and outcome as a function of
CXCL5 genotype. Statins improve outcomes in ACS in part
through anti-inflammatory properties. [14]. We previously
reported that basal endothelial ENA-78 production is modulated
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3117by atorvastatin [15]. Therefore, we also tested the hypothesis that
statin treatment may modify the association between CXCL5
genotypes and outcomes in our ACS cohort. Finally, to offer
insight into our epidemiological findings and validate CXCL5 as a
potential candidate in statin pharmacogenetics, we tested whether
atorvastatin treatment modulates CXCL5 expression and ENA-78
production from endothelial cells exposed to IL-1b, a model of
cardiovascular inflammation typical of ACS.
Results
Clinical Characteristics
The mean patient age was 61612 years, and the cohort was
comprised of 36% women and 79% Caucasians. Complete clinical
characteristics are displayed in Table 1. The minor allele
frequency for 2156C was 17%. Genotype frequencies did not
deviate from Hardy-Weinberg expectations. The patients were
similar when compared by CXCL5 2156G.C genotype with the
following exceptions: compared with G/G homozygotes, those
with the C/C genotype were slightly younger, less likely to be
Caucasian, had a greater prevalence of unstable angina as their
ACS type, had higher admission DBP, had higher discharge HDL,
and were less likely to be discharged on a statin (Table 1). G/C
heterozygotes generally exhibited the above phenotypes in a
fashion intermediate between G/G and C/C individuals. When
baseline characteristics were compared by genotype in Caucasians
alone, patients with the C/C genotype were older, but otherwise
had no significantly different characteristics from the other
genotype groups (Table 2).
Table 1. Baseline Characteristics.
Overall G/G G/C C/C P value
(n=704) (n=498) (n=175) (n=31)
Age 60.6612.4 61.4612.2 58.3612.5 60.0614.1 0.019
White 555 (79%) 437 (88%) 107 (61%) 11 (35%) ,0.0001
Women 253 (36%) 179 (36%) 60 (34%) 14 (45%) 0.51
ACS Type
Unstable angina 284 (40%) 188 (38%) 75 (43%) 21 (68%)
ST elevation MI 202 (29%) 154 (31%) 45 (26%) 3 (10%)
Non ST elevation MI 215 (31%) 154 (31%) 54 (31%) 7 (23%) 0.042
Old LBB/Unknown 3 (0.4%) 2 (0.4%) 1 (0.6%) 0 (0%)
History/risk factors:
Dyslipidemia 403 (57) 297 (60%) 91 (52%) 15 (48%) 0.113
Diabetes 197 (28) 136 (27%) 50 (29%) 11 (35%) 0.604
Heart failure 55 (8) 32 (6%) 19 (11%) 4 (13%) 0.0955
MI 238 (34) 168 (34%) 58 (33%) 12 (39%) 0.832
HTN 459 (65) 323 (65%) 114 (65%) 22 (71%) 0.787
BMI (kg/m2) 29.666.3 29.466.0 30.367.1 29.467.2 0.215
Smoking
Current 248 (35%) 168 (34%) 69 (40%) 11 (36%) 0.622
Former 258 (37%) 190 (38%) 56 (32%) 12 (39%)
Never 197 (28%) 140 (28%) 49 (28%) 8 (26%)
Disease severity
EF (n=670) 47.2612.8 46.8612.6 48.5613.4 47.0613.6 0.345
Admission SBP 136.6627.0 136.4626.8 135.9626.7 144.4631.0 0.257
Admission DBP 74.3616.7 72.8616.0 77.1617.5 81.2620.2 0.0009
Discharge total cholesterol* 178.7642.7 176.4640.6 184.7647.8 181.0643.0 0.118
Discharge HDL{ 41.9615.4 40.8612.7 44.3620.0 47.7622.1 0.0097
Discharge LDL{ 102.9637.3 100.7634.6 108.3643.0 107.2641.8 0.0957
Discharge triglycerides1 176.86122.7 181.36131.7 169.3699.4 141.3671.5 0.228
Treatment strategy
Medical management 259 (37%) 167 (34%) 75 (43%) 17 (55%) 0.048
PCI 414 (59%) 309 (62%) 92 (53%) 13 (42%)
CABG 31 (4%) 22 (4%) 8 (5%) 1 (3%)
Discharge statin 532 (76%) 390 (78%) 125 (71%) 17 (55%) 0.0044
*n=603;
{n=594;
{n=565;
1n=593; ACS=Acute coronary syndrome; MI=Myocardial infarction; LBB=Left bundle block; HTN=Hypertension; BMI=Body mass index;
EF=Ejection fraction; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HDL=High density lipoprotein; LDL=Low density lipoprotein; PCI=Percutaneous
coronary intervention; CABG=Coronary artery bypass graft.
doi:10.1371/journal.pone.0003117.t001
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CXCL5 2156 G.C genotype was significantly associated
with 3-year all-cause mortality in ACS patients. The death
rate was 10% in G/G, 13% in G/C, and 29% in C/C
individuals (p=0.005). C/C genotype was associated with a
hazard ratio of 3.09 (95% confidence interval [CI], 1.54–6.19;
p=0.002) compared to G/C+G/G genotypes (Figure 1A).
This effect remained significant when Caucasians alone were
analyzed (HR 4.0, 95%CI 1.45–11.05; p=0.008) (Figure 1B).
The increased risk of mortality remained significant after
adjustment for clinical covariates both in the overall popula-
tion (HR 2.65, 95%CI 1.19–5.87; p=0.017) (Figure 2A) and
in Caucasians alone (HR 3.25, 95%CI 1.04–10.13; p=0.043)
(Figure 2B).
Statin Interaction
We identified an interaction between discharge statin therapy
and CXCL5 2156 G.C genotype (p=0.09). Individuals with the
G/G genotype who were prescribed a statin at hospital discharge
had a significantly lower 3-year all-cause mortality rate compared
to those who did not receive a statin at hospital discharge (absolute
risk reduction 10.8%; relative risk reduction [RRR] 58.4%;
p=0.0009) (Figure 3). Statin benefit was diminished in the G/C
and C/C genotype groups. Patients with the G/C genotype
experienced a non-significant RRR of 25% when discharged on
statins (p=0.48), while patients with the C/C genotype prescribed
statin therapy had a numerically greater, although not significant,
mortality rate compared to those not prescribed statin therapy
(35.3% versus 21.4%, respectively; p=0.46) (Figure 3).
Table 2. Baseline Characteristics in Caucasians.
All Caucasians G/G G/C C/C P value
(n=555) (n=437) (n=107) (n=11)
Age 62.0612.5 62.1612.1 60.0613.1 72.1615.5 0.014
Women 194 (35%) 155 (35%) 32 (30%) 7 (64%) 0.073
ACS Type
Unstable angina 204 (37%) 159 (36%) 40 (37%) 5 (45%)
ST elevation MI 171 (31%) 137 (31%) 32 (30%) 2 (18%)
Non ST elevation MI 178 (32%) 139 (32%) 35 (33%) 4 (36%) 0.958
LBBB/Unknown 2 (0.4%) 2 (0.5%) 0 (0%) 0 (0%)
History/risk factors:
Dyslipidemia 324 (58%) 263 (60%) 57 (53%) 4 (36%) 0.134
Diabetes 134 (24%) 110 (25%) 21 (20%) 3 (27%) 0.472
Heart failure 30 (5%) 25 (6%) 4 (4%) 1 (9%) 0.619
MI 179 (32%) 142 (32%) 32 (30%) 5 (45%) 0.560
HTN 346 (62%) 280 (64%) 59 (55%) 7 (64%) 0.231
BMI (kg/m2) 29.465.9 29.465.8 29.866.1 28.865.8 0.762
Smoking
Current 180 (32%) 142 (32%) 35 (33%) 3 (27%) 0.766
Former 215 (39%) 174 (40%) 36 (34%) 5 (45%)
Never 159 (29%) 121 (28%) 35 (33%) 3 (27%)
Disease severity:
EF (n=532) 47.5612.4 47.1612.3 49.7612.0 44.1615.1 0.103
Admission SBP 134.2624.6 134.6625.0 133.3623.5 129.1622.3 0.695
Admission DBP 72.3614.9 71.9615.0 74.1614.6 71.0614.9 0.403
Discharge total cholesterol* 177.2640.9 175.8640.2 183.9643.2 165.8648.0 0.174
Discharge HDL{ 40.6614.8 40.2612.3 42.3622.6 38.8610.3 0.452
Discharge LDL{ 101.5634.9 100.1634.0 107.5636.9 100.8649.0 0.224
Discharge triglycerides1 185.06131.2 186.76136.9 181.76110.2 135.4648.5 0.574
Treatment strategy
Medical management 157 (28%) 132 (30%) 23 (22%) 2 (18%) 0.312
PCI 371 (67%) 283 (65%) 80 (75%) 8 (73%)
CABG 27 (5%) 22 (5%) 4 (4%) 1 (9%)
Discharge statin 439 (79%) 349 (80%) 82 (77%) 8 (73%) 0.665
*n=473;
{n=464;
{n=436;
1n=465; ACS=Acute coronary syndrome; MI=Myocardial infarction; LBB=Left bundle block; HTN=Hypertension; BMI=Body mass index;
EF=Ejection fraction; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HDL=High density lipoprotein; LDL=Low density lipoprotein; PCI=Percutaneous
coronary intervention; CABG=Coronary artery bypass graft.
doi:10.1371/journal.pone.0003117.t002
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Production from Endothelial Cells
To validate CXCL5/ENA-78 as an endothelial target for statins,
we utilized a HUVEC in vitro model of cardiovascular inflamma-
tion. There were no significant differences in HUVEC viability
between control conditions and any dose of atorvastatin ranging
from 1 mMt o5 0 mM (Figure 4). IL-1b increased ENA-78
production by nearly 60-fold relative to constitutive concentrations
(40756296 pg/mg vs. 6967 pg/mg; p,0.0001; Figure 5). Treat-
ment with atorvastatin attenuated this effect by 38%, 70%, 78%,
93%, and 99% in the five atorvastatin dose groups (p,0.001 for
all comparisons vs. IL-1b).
The time-dependent course of ENA-78 changes relative to
control in response to IL-1b and atorvastatin/IL-1b co-treatment
are shown in Figure 6. Atorvastatin’s time effect was significant at
24 hours and most pronounced at 48 hours. Specifically, atorvas-
tatin attenuated IL-1b stimulated production of ENA-78 at 4, 12,
24, and 48 hours by 0%, 30%, 59% (p=0.01), and 76%
(p=0.009), respectively.
To determine whether atorvastatin effects were dependent on
HMG-CoA reductase inhibition, HUVECs were cultured with IL-
1b and atorvastatin 10 mM in the presence or absence of
mevalonate. To assess whether downstream products of mevalo-
nate biosynthesis are implicated in the drug effect, conditions also
included cultures in the presence or absence of FPP and GGPP
(Figure 7). Consistent with the previous experiments, atorvastatin
significantly attenuated IL-1b-stimulated ENA-78 production
(31816407 pg/mg vs. 10546234 pg/mg; p,0.001). Co-treat-
ment with mevalonate and FPP reversed the effect of atorvastatin
(p=NS vs. IL-1b), and GGPP partially reversed the effect of
atorvastatin (p=0.05 vs. IL-1b).
Atorvastatin significantly lowered constitutive expression of
CXCL5 (p,0.005), while IL-1b significantly induced CXCL5
expression in HUVECs at 24 hours (p,0.0001). However, pre-
treatment of HUVECs with atorvastatin did not blunt IL-1b
induction of CXCL5 expression (Figure 8).
Figure 1. Kaplan Meier estimates for all-cause mortality by CXCL5 2156 G.C genotype. Panel A represents the overall population; panel B
represents the Caucasians only.
doi:10.1371/journal.pone.0003117.g001
Figure 2. Adjusted hazard ratio and 95% confidence intervals
for all-cause mortality by genotype. Top panel is overall
population (p=0.017) and bottom panel is Caucasians only
(p=0.043). Models adjusted for age, race, sex, ACS type, revasculariza-
tion strategy, history of diabetes, and history of heart failure.
doi:10.1371/journal.pone.0003117.g002
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In the current analysis, we demonstrate that a common
promoter polymorphism in the ENA-78 gene (CXCL5)i s
associated with 3-year all-cause mortality in ACS patients, adding
further support for a role of neutrophil chemoattractants in acute
ischemic syndromes. Even after adjustment for age, sex, ACS type,
revascularization strategy, heart failure, and diabetes, patients with
two copies of the 2156C variant allele were at 2.7-fold higher risk
for mortality than patients with at least one copy of the 2156G
wild-type allele. The overall death rates for G/G, G/C, and C/C
individuals were 10%, 13%, and 29%, respectively.
Importantly, we also demonstrated a pharmacogenetic relation-
ship between CXCL5 genotypes and discharge statin use. G/G
patients experienced a significant RRR of 58% in all-cause
mortality; G/C heterozygotes experienced a non-significant
reduction of 25%; and C/C homozygotes experienced a non-
significant increase of 39%. Our findings of an association between
discharge statin use and mortality, as a function of CXCL5
genotype, is an important extension of previous work. Several lines
of evidence suggest that part of the cardioprotective effect of statins
is related to their ability to modulate neutrophil function by
various mechanisms, including reduced production of neutrophil
chemokines [16–20]. Our findings that the absolute mortality rate
was numerically higher in C/C homozygotes discharged on a
statin compared with C/C homozygotes not discharged on a statin
is congruent with findings regarding the influence of statins on
NAP-2, a neutrophil-activating chemokine exhibiting over 50%
homology with ENA-78 [21]. Smith and colleagues demonstrated
elevated NAP-2 plasma concentrations in patients with unstable
angina [21]. However, while aspirin lowered plasma NAP-2, statin
treatment stimulated NAP-2 production in patients, peripheral
blood mononuclear cells, and platelets. This pro-inflammatory
effect has also been observed by others; Kiener and colleagues
demonstrated that some, but not all, statins stimulate monocyte
production of pro-inflammatory cytokines including IL-8 (22%
homology with ENA-78) in vitro and increase influx of leukocyte
subtypes (including neutrophils) in vivo [22]. Therefore, while there
is a strongly beneficial effect of statin therapy in the general
population, some subsets of ACS patients may not derive such
benefit. We have previously demonstrated CXCL5 2156C carriers
exhibit significantly greater plasma concentrations of ENA-78 and
greater ENA-78 production from cultured leukocytes [13].
Therefore, it is conceivable that patients with the 2156 C/C
genotype may simultaneously represent a population at higher risk
for ACS mortality that experiences little, if any, benefit from
discharge statin therapy. The exact mechanism of this observation
warrants further investigation.
In addition to our epidemiological analyses, we performed in
vitro experiments and showed that CXCL5/ENA-78 is an
endothelial target for statins. We corroborated previous work
which showed ENA-78 is highly inducible by IL-1b in endothelial
cells [6,7,9]. In the current experiments, atorvastatin modulated
IL-1b-mediated ENA-78 production in a dose- and time-specific
manner, through pathways involving HMG-CoA reductase and
prenylation proteins. The drug effect began as early as 12 hours
after stimulation and persisted out to 48 hours with no signs of
diminishment. It has been hypothesized that statins exhibit early
anti-inflammatory effects that may explain their benefit in acute
manifestations of CVD (e.g., ACS). Furthermore, it has been
Figure 3. All-cause mortality rate by genotype among statin-treated and non-treated patients. *p=0.0009., {p=0.48; {p=0.46.
doi:10.1371/journal.pone.0003117.g003
Figure 4. Cell viability of HUVECs cultured for 24 hours with
atorvastatin. Data are presented as mean6SEM of 3 experiments.
*p,0.0001. AT, atorvastatin.
doi:10.1371/journal.pone.0003117.g004
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settings result in demonstrable improvement in outcomes [23–25].
Our data suggest that early and persistent inhibition of IL-1b-
induced endothelial ENA-78 production should be considered part
of the spectrum of statin pleiotropism, and may represent an
important mechanism of statin benefit in ACS and conditions
marked by neutrophil involvement.
While postulated to be independent of LDL lowering, the anti-
inflammatory effects of statins are thought to result from HMG-
CoA reductase inhibition and/or inhibited production of prenyla-
tion precursors, such as FPP and GGPP. Our findings support this
body of evidence in that atorvastatin’s modulatory effect on ENA-
78 was reversed by the addition of mevalonate and FPP, and
partially reversed by GGPP. Previous studies have explored the
effects of FPP and GGPP on statin responses, with the hope of
elucidating the contribution of prenylation pathways on drug
effects. Reversal of statin effects in vitro by the addition of FPP and
Figure 5. Atorvastatin attenuates IL-1b-induced ENA-78 production in a dose-dependent fashion. Data are presented as mean6SEM of
4 experiments. * p,0.0001 vs. IL-1b, {p=NS vs. control. AT, atorvastatin.
doi:10.1371/journal.pone.0003117.g005
Figure 6. Atorvastatin attenuates ENA-78 production over
time. Levels are relative to baseline (0 hour) for each condition. Data
are presented as mean6SEM of 4 experiments. *p#0.01. —#—, IL-1b
stimulation+atorvastatin 10 mM; —N—, IL-1b stimulation alone; AT,
atorvastatin.
doi:10.1371/journal.pone.0003117.g006
Figure 7. Atorvastatin effects on ENA-78 are reversed by
mevalonate and its downstream metabolites. Data are presented
as mean6SEM of 10 experiments. *p,0.001 and {p=0.05 compared to
IL-1b stimulation alone. AT, atorvastatin; FPP, farnesyl pyrophosphate;
GGPP, geranylgeranyl pyrophosphate; MEV, mevalonate.
doi:10.1371/journal.pone.0003117.g007
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studies have shown that either Ras or Rho signaling may be
involved in the statin effect, depending on the specific drug
response tested [26–29].
While we showed atorvastatin to lower endothelial ENA-78
protein production under pro-inflammatory conditions, we also
investigated whether atorvastatin lowered CXCL5 expression. We
found a significant reduction in basal CXCL5 expression with
atorvastatin treatment that was not observed for conditions with
IL-1b stimulation. Nonetheless, we have previously shown basal
endothelial ENA-78 protein production to be reduced by
atorvastatin in a dose-dependent fashion, and currently extend
this observation to a pro-inflammatory state [15]. There are
several possible reasons for the disparate impact of atorvastatin on
CXCL5 expression in non-stimulated and stimulated conditions.
Firstly, in a pro-inflammatory state (such as that induced by IL-
1b), the predominant statin effect may be post-transcriptional in
nature. Similar findings have been reported for the effect of
rosuvastatin on MMP-7 production and expression whereby
protein production but not gene expression was lowered [30]. A
second explanation can be found from recent studies that
implicate geranylgeranylation as an important homeostatic
mechanism in IL-1b secretion from macrophages and peripheral
blood mononuclear cells [31,32]. Specifically, it was demonstrated
that inhibition of isoprenoid production with statins led to
upregulation of IL-1b. This effect was more pronounced upon
addition of exogenous IL-1b (as in our experiments) suggesting
that depletion of isoprenoids by statins shuts off the IL-1b negative
feedback loop. As such, one can speculate that co-treatment of
HUVECs with IL-1b and atorvastatin in our experiments may
have potentiated IL-1b autocrine activity. Since CXCL5 is highly
inducible by IL-1b in HUVECs, the preponderant drug effect
manifested as a reduction of ENA-78 protein concentrations
(presumable through a post-transcriptional mechanism) with no
impact on CXCL5 expression.
There are several limitations to our analysis. Because of the
epidemiological nature of the cohort study, data on white blood
cell counts and differentials were unavailable. Therefore, the effect
of these parameters on clinical endpoints in our population could
not be directly tested. Along these lines, blood samples were not
available to directly quantify ENA-78 protein concentrations in
our patients. Nonetheless, we have previously shown that CXCL5
genotype is a predictor of circulating ENA-78 concentrations and
leukocyte production of ENA-78 [13]. Furthermore, the CXCL5
genotype may in fact be a more stable marker of ACS risk than
circulating ENA-78 concentrations since protein concentrations
are more likely to be influenced by multiple stress-related factors.
We have, in fact, shown this to be the case whereby endothelial
nitric oxide (NO) synthase (NOS3) genotype was robustly
associated with arterial stiffness, while circulating surrogate
markers of NO activity (serum superoxide dismutase and nitrite)
were not [33,34]. We noted an interaction between discharge
statin use and CXCL5 genotype on outcomes. Because we did not
have drug-specific information, we could not determine if this
effect was differential influenced by the specific statin used, or the
type of statin (i.e., hydrophilic vs. lipophilic); nor would we likely
have the power to conduct such an analysis if the data were
available. We also do not have information on the persistence of
discharge statin use over time in these patients. Additionally,
because of the small sample size for this subgroup analysis, there is
a possibility of a false positive finding between genotype and
discharge statin use. Nonetheless, others have estimated persis-
tence of discharge statin use to be nearly 80% among patients
similar in characteristics to our own [35]. In addition, our in vitro
endothelial experiments validated ENA-78/CXCL5 as an endo-
thelial target of statin action in an inflammatory environment
typical of ACS, adding biological plausibility to our epidemiolog-
ical finding. Finally, because of the lack of granularity in the Social
Security Administration Death Master File, the exact cause of
mortality could not be determined. This is a known limitation of
epidemiologic data and further analyses in independent cohorts
are warranted. Despite these limitations, our data suggest that the
ENA-78 gene, CXCL5, is associated with post-ACS all-cause
mortality and is an endothelial target of atorvastatin in vitro.
Whether ENA-78 modulation by statins is a central mediator of
drug benefit in ACS is unknown. However, our findings strongly
suggest a role of ENA-78 and CXCL5 genetic variants as
determinants of CVD and drug response.
Methods
Acute Coronary Syndrome Cohort and Gene/SNP
Selection
The methods of accrual and adjudication for this prospective
cohort have been previously described [36]. Briefly, patients with a
confirmed ACS were enrolled from two Kansas City hospitals.
Myocardial infarction (MI) was defined by elevated troponin level
in combination with chest pain symptoms or electrocardiographic
findings (ST-segment elevation or non-ST-segement elevation)
Figure 8. CXCL5 expression is modulated by atorvastatin and
IL-1b. (A) Gel electrophoresis of CXCL5 and GAPDH PCR products; (B)
Log10 relative quantification of CXCL5 modulated by atorvastatin, IL-1b,
and their combination normalized to GAPDH (N=2 experiments).
*P,0.005, {P,0.0001. AT, atorvastatin.
doi:10.1371/journal.pone.0003117.g008
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troponin level and any one of the following: new-onset angina (,2
months), prolonged angina (.20 minutes) at rest, recent worsen-
ing angina, or angina that occurred within 2 weeks of MI [37].
Demographic information was obtained from patient interviews
during hospital admission. Medical history, medication history,
laboratory values, and inpatient treatment during the ACS
hospitalization were obtained from chart abstractions. The Social
Security Administration Death Master File (http://www.ntis.gov/
products/ssa-dmf.asp) was queried approximately once yearly to
obtain three-year all-cause mortality assessment. The study was
approved by the institutional review boards of both institutions
and written informed consent was obtained from all participants.
Participants were genotyped according to previously published
methods [38]. CXCL5 (MIM 600324) was chosen as our a priori
candidate gene based on 1) the known role of the neutrophil
pathway in cardiovascular diseases including ACS [39–41], and 2)
our previously published data demonstrating atorvastatin to
significantly lower basal production of endothelial ENA-78 [15].
The 2156G.C SNP (rs352046) was chosen as our candidate SNP
because of our previous work demonstrating this SNP to be
associated with variable ENA-78 protein concentration in vivo [13].
In Vitro Endothelial Experiments
Cell Culture and Reagents. Human umbilical vein
endothelial cells (HUVECs) (Lonza Walkersville, Inc.,
Walkersville, MD) were cultured as previously described [15].
Briefly, HUVECs between passes three and four were seeded at a
density of 2.5610
4 cells per cm
2 and cultured to 80% confluence
with endothelial cell growth–supplemented medium. Once
confluent, media were changed to serum free endothelial basal
media for 24 hours prior to treatment after which basal media
supplemented to 2% FBS concentration was used.
Treatments consisted of atorvastatin calcium (LKT Laborato-
ries Inc., St. Paul, MN) 1–50 mM dissolved in dimethyl sulfoxide
(DMSO). IL-1b, mevalonate, farnesyl pyrophosphate (FPP), and
geranylgeranyl pyrophosphate (GGPP; all from Sigma-Aldrich, St.
Louis, MO) were all dissolved in molecular grade water and used
at concentrations of 2 ng/ml, 250 mM, 5 mM, and 5 mM
respectively. All final DMSO concentrations were less then 0.1%.
Treatments. Cell viability was assessed by trypan blue
staining. In experiments investigating the impact of atorvastatin
dose on ENA-78 production, HUVECs were pre-treated with
atorvastatin followed by addition of IL-1b two hours later. After
dose-ranging studies were performed, the time-dependent effects
of atorvastatin were investigated at 0, 4, 12, 24, and 48 hours. In
separate experiments, cells were cultured with IL-1b and
atorvastatin in the presence or absence of mevalonate, FPP, and
GGPP to determine whether atorvastatin inhibition of ENA-78
production was dependent on HMG-CoA reductase inhibition
and subsequent downstream pathways. Cell culture supernates for
all experiments were stored at 220uC until analysis, which was
performed within seven days.
Protein Quantification and Gene Expression. ENA-78
concentrations were measured and normalized to total protein
content using cytometric immunofluorescence as previously
described [15]. Ribonucleic acid (RNA) was isolated using a
commercial kit (RNeasy mini kit, Qiagen Inc., Valencia, CA).
Complementary deoxyribonucleic acid (cDNA) conversion was
performed by high capacity cDNA reverse transcription (Applied
Biosystems, Foster City, CA) per protocol using roughly 2 mgo f
total RNA. RNA quality was assessed by absorbance (Nanodrop,
Nanodrop Technologies, Wilmington, DE). Real-time reverse-
transcription PCR (RT-PCR) was performed using primer and
probe sets for CXCL5 normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Taqman
Gene Expression Assays, Applied Biosystems Inc.). Relative
quantification was verified by gel electrophoresis of PCR
products using exonic primers for CXCL5 (5-CGGG-
AAGGAAATTTGTCTTGA-3; 5-AGCTTAAGCGGCAAAC-
ATAGG-3) and GAPDH (5-AAAATCAAGTGGGGCGATGC-
T-3; 5-GCCAGGGGTGCTAAGCAGTT-3). PCR for both
CXCL5 and GAPDH were performed in parallel reactions using
the following conditions: 95uC for 2 minutes; 35 cycles of 95uC for
30 seconds, 59uC for 30 seconds, and 72uC for 30 seconds;
followed by 7 minutes of elongation at 72uC.
Statistical Analyses
ACS Cohort. Baseline characteristics were compared by
ANOVA, student’s t-test or chi-square tests as appropriate.
Allele frequencies were calculated by allele counting and
deviations from Hardy-Weinberg equilibrium were tested by chi-
square. Death rates were compared by chi-square or Fisher’s exact
tests. To minimize multiple testing and maximize statistical power,
one mode of inheritance was tested (recessive) only after visual
inspection of survival curves for all three genotype groups. We had
80% power to detect a hazard ratio of 1.57 under the tested
recessive model of inheritance, given our sample size of 704
participants and a minor allele frequency of 17%.
Cox proportional hazards models were developed that included
the following pre-specified covariates: age, sex, ACS type (ST
elevation MI, non ST elevation MI, or unstable angina), coronary
revascularization strategy (medical management, percutaneous
coronary intervention, or coronary artery bypass graft), heart
failure, diabetes, and CXCL5 genotype. Additionally, interactions
between genotype and discharge statin use were assessed in the
models. All models were conducted in the overall population and
separately by race to minimize confounding by population
stratification. Survival plots were generated by the Kaplan-Meier
technique. The statin*genotype interaction term was considered
significant if p,0.1 (two-sided) since multiplicative interaction
testing is generally not powered to detect significance at an
a=0.05 [42]. In all other analyses, p,0.05 was considered
significant. SAS version 9.1 was used for all analyses.
In Vitro Experiments. ENA-78 protein concentrations and
CXCL5 gene expression levels were compared for all conditions by
one-way ANOVA with Tukey correction for multiple
comparisons. An independent t-test was used to compare
treatment differences at each time point in the time-course
studies. Relative CXCL5 gene expression was determined by the
2
2DDCt method [43]. A p-value,0.05 was considered significant.
Statistical analyses were performed with SPSS software, version
11.5 (SPSS Inc., Chicago, USA). The authors had full access to the
data and take responsibility for its integrity. All authors have read
and agree to the manuscript as written.
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